WO2012010641A3 - Pharmaceutical composition for increasing cellular hypoxic tolerance - Google Patents

Pharmaceutical composition for increasing cellular hypoxic tolerance Download PDF

Info

Publication number
WO2012010641A3
WO2012010641A3 PCT/EP2011/062469 EP2011062469W WO2012010641A3 WO 2012010641 A3 WO2012010641 A3 WO 2012010641A3 EP 2011062469 W EP2011062469 W EP 2011062469W WO 2012010641 A3 WO2012010641 A3 WO 2012010641A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
increasing cellular
hypoxic conditions
hypoxic tolerance
ischemic
Prior art date
Application number
PCT/EP2011/062469
Other languages
French (fr)
Other versions
WO2012010641A2 (en
Inventor
Christian Frelin
Paul Vigne
Michel Tauc
Isabelle Rubera
Christophe Duranton
Marc Cougnon
Nicolas Blondeau
Original Assignee
Universite De Nice Sophia Antipolis
Centre National De La Recherche Scientifique (Cnrs)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite De Nice Sophia Antipolis, Centre National De La Recherche Scientifique (Cnrs) filed Critical Universite De Nice Sophia Antipolis
Publication of WO2012010641A2 publication Critical patent/WO2012010641A2/en
Publication of WO2012010641A3 publication Critical patent/WO2012010641A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The present inventors have discovered a new class of cryoprotective therapeutic agents which make it possible for mammalian cells to survive for longer periods of time under hypoxic conditions, and to prevent problems linked to oxygen deprivation in a model of renal failure due to ischemic lesion in rats and of cardiac stroke. The present invention is therefore directed towards a pharmaceutical composition for preventing and/or treating pathological conditions resulting from hypoxic conditions and/or from ischemic lesions in a mammal, said composition comprising, as cytoprotective agent, an elF5A-hypusination-inhibiting agent, such as, for example, N1-guanyl-1,7-diaminoheptane (GC7).
PCT/EP2011/062469 2010-07-20 2011-07-20 Pharmaceutical composition for increasing cellular hypoxic tolerance WO2012010641A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1055910A FR2962906A1 (en) 2010-07-20 2010-07-20 USE OF INHIBITORS OF HYPUSINYLATION OF eIF5A TO TREAT ISCHEMIC AND HYPOXIC DISEASES
FR1055910 2010-07-20

Publications (2)

Publication Number Publication Date
WO2012010641A2 WO2012010641A2 (en) 2012-01-26
WO2012010641A3 true WO2012010641A3 (en) 2012-04-12

Family

ID=43416485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/062469 WO2012010641A2 (en) 2010-07-20 2011-07-20 Pharmaceutical composition for increasing cellular hypoxic tolerance

Country Status (2)

Country Link
FR (1) FR2962906A1 (en)
WO (1) WO2012010641A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578180A1 (en) 2018-06-05 2019-12-11 Centre National de la Recherche Scientifique (CNRS) Modulators of seryl-trna synthase and pharmaceutical compositions comprising the same for increasing cell hypoxic tolerance

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106433A1 (en) * 2002-06-12 2003-12-24 Viaxxel Biotech Gmbh Deoxyhypusine-synthase inhibitors, pharmaceuticals comprising said inhibitors and uses thereof
US20050282909A1 (en) * 2003-11-14 2005-12-22 Diks Sander H Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction
WO2009144933A1 (en) * 2008-05-27 2009-12-03 国立大学法人東京大学 Apoptosis inducer
WO2010118224A1 (en) * 2009-04-08 2010-10-14 Indiana University Research And Technology Corporation Preventing islet inflammation and dysfunction and maintaining proper glucose levels by controlling elf5a and its hypusination

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959010A3 (en) 2004-12-03 2009-02-25 Senesco Technologies, Inc. Apoptosis-specific eif-5A and polynucleotides encoding same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106433A1 (en) * 2002-06-12 2003-12-24 Viaxxel Biotech Gmbh Deoxyhypusine-synthase inhibitors, pharmaceuticals comprising said inhibitors and uses thereof
US20050282909A1 (en) * 2003-11-14 2005-12-22 Diks Sander H Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction
WO2009144933A1 (en) * 2008-05-27 2009-12-03 国立大学法人東京大学 Apoptosis inducer
US20110177089A1 (en) * 2008-05-27 2011-07-21 The University Of Tokyo Apoptosis inducer
WO2010118224A1 (en) * 2009-04-08 2010-10-14 Indiana University Research And Technology Corporation Preventing islet inflammation and dysfunction and maintaining proper glucose levels by controlling elf5a and its hypusination

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CAMPBELL R A ET AL: "Effects of DL-alpha-difluoromethylornithine, 4-deoxypyridoxine and methylglyoxal bis(guanylhydrazone) on allograft prolongation", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 48, no. 3, 1 January 1991 (1991-01-01), pages 225 - 235, XP025525969, ISSN: 0024-3205, [retrieved on 19910101], DOI: DOI:10.1016/0024-3205(91)90349-G *
COCKROFT K M ET AL: "A NOVEL INHIBITOR OF INFLAMMATORY CYTOKINE PRODUCTION (CNI-1493) IS CEREBROPROTECTIVE IN PERMANENT FOCAL CEREBRAL ISCHEMIA", SURGICAL FORUM, CHICAGO, US, vol. 47, 1 January 1996 (1996-01-01), pages 568 - 570, XP009011873, ISSN: 0071-8041 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 5 May 2010 (2010-05-05), WANG, JIAN-MING ET AL: "Role of p38 MAPK in ischemia/reperfusion-induced gastric injury in mice", XP002659982, retrieved from STN Database accession no. 2010:556109 *
DATABASE WPI Week 200981, Derwent World Patents Index; AN 2009-R98837, XP002617010 *
DIER JUNYI DAXUE XUEBAO , 31(3), 250-253 CODEN: DJXUE5; ISSN: 0258-879X, 2010 *
HALL ET AL: "Prevention of ischemia/reperfusion-induced alterations in synaptosomal membrane-associated proteins and lipids by N-tert-butyl-alpha-phenyln itrone and difluoromethylornithine", NEUROSCIENCE, NEW YORK, NY, US, vol. 69, no. 2, 1 November 1995 (1995-11-01), pages 591 - 600, XP022251193, ISSN: 0306-4522, DOI: DOI:10.1016/0306-4522(95)00289-U *
HUANG Y ET AL: "Neuronal growth and survival mediated by eIF5A, a polyamine-modified translation initiation factor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 20070306 US LNKD- DOI:10.1073/PNAS.0611609104, vol. 104, no. 10, 6 March 2007 (2007-03-06), pages 4194 - 4199, XP002617014, ISSN: 0027-8424 *
IGARASHI K ET AL: "Modulation of cellular function by polyamines", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, EXETER, GB, vol. 42, no. 1, 1 January 2010 (2010-01-01), pages 39 - 51, XP026909603, ISSN: 1357-2725, [retrieved on 20090728], DOI: DOI:10.1016/J.BIOCEL.2009.07.009 *
LANDAU GUY ET AL: "The Role of Polyamines in Supporting Growth of Mammalian Cells Is Mediated through Their Requirement for Translation Initiation and Elongation", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 17, April 2010 (2010-04-01), pages 12474 - 12481, XP002617012, ISSN: 0021-9258 *
LUKKARINEN J A: "Neuroprotective role of ornithine decarboxylase activation in transient focal cerebral ischaemia: A study using ornithine decarboxylase-overexpressing transgenic rats", EUROPEAN JOURNAL OF NEUROSCIENCE 1998 GB LNKD- DOI:10.1046/J.1460-9568.1998.00216.X, vol. 10, no. 6, 1998, pages 2046 - 2055, XP007916757, ISSN: 0953-816X *
MINANOV O P ET AL: "AN INHIBITOR OF MACROPHAGE PROINFLAMMATORY CYTOKINES AND NITRIC OXIDE PRODUCTION (CNI-1493) PROLONGS GRAFT LIFE IN TRANSPLANTED RAT HEARTS", SURGICAL FORUM, CHICAGO, US, vol. 47, 1 January 1996 (1996-01-01), pages 418 - 420, XP008012780, ISSN: 0071-8041 *
SAUER D ET AL: "Differing effects of alpha-difluoromethylornithine and CGP 40116 on polyamine levels and infarct volume in a rat model of focal cerebral ischaemia", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 141, no. 2, 20 July 1992 (1992-07-20), pages 131 - 135, XP024363460, ISSN: 0304-3940, [retrieved on 19920720], DOI: DOI:10.1016/0304-3940(92)90878-B *
VIGNE P ET AL: "The role of polyamines in protein-dependent hypoxic tolerance of Drosophila", BMC PHYSIOLOGY 2008 GB LNKD- DOI:10.1186/1472-6793-8-22, vol. 8, no. 1, 2008, XP021049518, ISSN: 1472-6793 *

Also Published As

Publication number Publication date
WO2012010641A2 (en) 2012-01-26
FR2962906A1 (en) 2012-01-27

Similar Documents

Publication Publication Date Title
WO2011109799A8 (en) Nuclear transport modulatiors and uses thereof
EP3085365A3 (en) Synergistic combinations of carotenoids and polyphenols
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
WO2013066835A3 (en) Compounds and methods
MX2019010341A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels.
MX2014001180A (en) Nuclear transport modulators and uses thereof.
WO2011034627A3 (en) Methods and apparatus for introducing cells at a tissue site
ECSP13012692A (en) INHIBITING TRICYCLIC COMPOUNDS OF THE PI3K AND METHODS OF USE
DK2231662T3 (en) 8-Anilinoimidazopyridines and their use as anticancer and / or anti-inflammatory agents
EA201200046A1 (en) NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND RELATED METHODS
EA201100136A1 (en) 2,4'-BIPIRIDINILES AS PROTEINKINASE DIOR INHIBITORS APPLICABLE FOR THE TREATMENT OF HEART FAILURE AND CANCER
MY190361A (en) 2-acylaminothiazole derivative or salt thereof
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
WO2012092420A3 (en) Methods for cryopreserving and encapsulating cells
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
WO2009100137A3 (en) Magnetic cells for localizing delivery and tissue repair
WO2011106322A3 (en) Biomarkers for acute ischemic stroke
WO2011146879A3 (en) Methods and compositions related to modulating autophagy
MY161001A (en) Tetrahydrocarboline Derivative
MX2013002584A (en) Pyrazoloquinoline compound.
GT201200164A (en) "NEW SPYROPIPERIDINE COMPOUNDS"
WO2010135401A3 (en) Kinase-mediated cytoprotection and enhanced cellular engraftment and persistence
WO2012106551A1 (en) Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
CL2013003676A1 (en) Composition of herbicide granule comprising 5-50 gai / kg of an aryloxyphenoxypropionic acid herbicide, 20-200 g / kg of an integrated adjuvant not derived from petroleum, 700-950 g / kg of a solid water soluble vehicle and 1 -50 g / kg of a surface active agent; method of control of undesirable vegetation in an aquatic environment, such as a rice field or a rice field.
MX2013006188A (en) Apoptosis pet imaging agents.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11736342

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11736342

Country of ref document: EP

Kind code of ref document: A2